Previous close | 2.9000 |
Open | 2.9900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 43.00 |
Expiry date | 2024-08-16 |
Day's range | 2.9000 - 3.3000 |
Contract range | N/A |
Volume | |
Open interest | 958 |
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML and TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Iran State TV Says ‘No Sign of Life’ a
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
Drugmaker GlaxoSmithKline Pharma India reported a 49% rise in fourth-quarter adjusted profit on Friday, as strong demand for its generic medicines offset the impact of the government's ongoing price curbs on its key drugs. Revenue from operations rose 18% to 9.30 billion rupees, led by a 12% growth in its generic medicines portfolio which the company attributed to key focus brands Augmentin, Ceftum and Calpol. Earnings at drugmakers like GlaxoSmithKline Pharma and Abbott India have been pressured as prices of some of their key drugs were capped under the Indian government's essential medicines list (NLEM) since September 2022.